Partnering Opportunities

OUT-LICENSING OPPORTUNITIES – Protox is evaluating potential partners to either co-develop or out-license the development and commercialization of PRX302 for prostate cancer and benign prostatic hyperplasia (BPH) programs. Potential partners must have the commercial infrastructure and resources necessary to effectively develop and promote PRX302 for these significant markets.

IN-LICENSING AND COLLABORATION OPPORTUNITIES – In order to leverage the company’s core expertise in targeted toxin-based therapeutics, Protox is actively seeking partnerships focusing on the discovery and development of immunotoxins or fusion proteins that combine the specificity of receptor targeted antibodies or ligands with the selective proteolytic activation of PORxin™ drug candidates. We believe that such dual targeting will offer an improved therapeutic window compared to either approach alone.

If you are interested in exploring either of these opportunities, please contact

Shafique Fidai,
Senior Director, Corporate Development
business@protoxtherapeutics.com

What's New

June 2 2010
Protox Announces Positive Six Month Phase 2B BPH Results

June 1, 2010
Protox to Present Phase 2B BPH Data at the Annual Meeting of the American Urological Association

May 13, 2010
Protox Reports First Quarter 2010 Financial Results

April 29, 2010
Protox Signs $75 Million License Agreement with Kissei for Commercialization of PRX302 in Japan for BPH and Prostate Disease

 

Events

January 11, 2010 - 8:45 am ET
Protox Therapeutics Conference Call - Webcast Link

 

Stock Quote

LAST TRADE:$0.39
TRADE TIME:3:53PM EST
CHANGE:$0.00 (0.00%)
PREV CLOSE: $0.39
OPEN:$0.39
BID:$0.385
ASK:$0.39